Featured Content
FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Bispecific Antibodies in Cancer
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
Triclosan and Cancer Risk: Is There a Link?
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.More Features>>>
Endocrine Cancer Resources
More Information
Finding Clinical Trials in Cancer
September 21, 2018
This fact sheet describes patient-directed strategies for finding clinical trials.
Managing Immune-Related Adverse Events
September 14, 2018
An overview of the potential immune-related adverse events that can arise from treatment with checkpoint inhibitors.
Managing Neutropenia
September 07, 2018
Both the chemotherapy regimen selected and therapeutic dose intensity used in treatment factor into the calculation of neutropenia risk.
Genetic Testing and Cancer
August 24, 2018
Traditional genetic testing historically included the sequential analysis of single and generally well-described genes involved in heritable cancers.
Psychotherapy and Cancer
August 17, 2018
Some data suggest that psychotherapy may benefit patients with cancer, but higher-quality research is needed.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Prostate Cancer | Regimens | Drugs |
| Rare Cancers | Regimens | |
| Renal Cell Carcinoma | Regimens | Drugs |
| Skin Cancer | Regimens | Drugs |
| Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML